These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 31691633)

  • 1. Selection of the optimal personalized treatment from multiple treatments with multivariate outcome measures.
    Siriwardhana C; Datta S; Kulasekera KB
    J Biopharm Stat; 2020 May; 30(3):462-480. PubMed ID: 31691633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal Personalized Treatment Selection with Multivariate Outcome Measures in a Multiple Treatment Case.
    Siriwardhana C; Kulasekera KB
    Commun Stat Simul Comput; 2023; 52(12):5773-5787. PubMed ID: 38371330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantiles based personalized treatment selection for multivariate outcomes and multiple treatments.
    Kulasekera KB; Siriwardhana C
    Stat Med; 2022 Jul; 41(15):2695-2710. PubMed ID: 35699385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-Response Based Personalized Treatment Selection with Data from Crossover Designs for Multiple Treatments.
    Kulasekera KB; Siriwardhana C
    Commun Stat Simul Comput; 2022; 51(2):554-569. PubMed ID: 35299995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Personalized treatment selection using data from crossover designs with carry-over effects.
    Siriwardhana C; Kulasekera KB; Datta S
    Stat Med; 2019 Dec; 38(28):5391-5412. PubMed ID: 31637762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection of the optimal personalized treatment from multiple treatments with right-censored multivariate outcome measures.
    Siriwardhana C; Kulasekera KB; Datta S
    J Appl Stat; 2024; 51(5):891-912. PubMed ID: 38524800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A probability based method for selecting the optimal personalized treatment from multiple treatments.
    Siriwardhana C; Zhao M; Datta S; Kulasekera KB
    Stat Methods Med Res; 2019 Mar; 28(3):749-760. PubMed ID: 29145777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalized treatment plans with multivariate outcomes.
    Siriwardhana C; Kulasekera KB
    Biom J; 2020 Dec; 62(8):1973-1985. PubMed ID: 32627863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Framework for personalized prediction of treatment response in relapsing remitting multiple sclerosis.
    Stühler E; Braune S; Lionetto F; Heer Y; Jules E; Westermann C; Bergmann A; van Hövell P;
    BMC Med Res Methodol; 2020 Feb; 20(1):24. PubMed ID: 32028898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying treatment responders using counterfactual modeling and potential outcomes.
    Porcher R; Jacot J; Wunder JS; Biau DJ
    Stat Methods Med Res; 2019; 28(10-11):3346-3362. PubMed ID: 30298794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating the Optimal Personalized Treatment Strategy Based on Selected Variables to Prolong Survival via Random Survival Forest with Weighted Bootstrap.
    Shen J; Wang L; Daignault S; Spratt DE; Morgan TM; Taylor JMG
    J Biopharm Stat; 2018; 28(2):362-381. PubMed ID: 28934002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A conditional error function approach for subgroup selection in adaptive clinical trials.
    Friede T; Parsons N; Stallard N
    Stat Med; 2012 Dec; 31(30):4309-20. PubMed ID: 22865774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On Enrichment Strategies for Biomarker Stratified Clinical Trials.
    Wang X; Zhou J; Wang T; George SL
    J Biopharm Stat; 2018; 28(2):292-308. PubMed ID: 28933670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A class of Covariate-Adjusted Response-Adaptive Allocation Designs for Multitreatment Binary Response Trials.
    Biswas A; Bhattacharya R
    J Biopharm Stat; 2018; 28(5):809-823. PubMed ID: 29913107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Bayesian multivariate hierarchical model for developing a treatment benefit index using mixed types of outcomes.
    Wu D; Goldfeld KS; Petkova E; Park HG
    BMC Med Res Methodol; 2024 Sep; 24(1):218. PubMed ID: 39333874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of randomized comparative clinical trial data for personalized treatment selections.
    Cai T; Tian L; Wong PH; Wei LJ
    Biostatistics; 2011 Apr; 12(2):270-82. PubMed ID: 20876663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced precision in the analysis of randomized trials with ordinal outcomes.
    Díaz I; Colantuoni E; Rosenblum M
    Biometrics; 2016 Jun; 72(2):422-31. PubMed ID: 26576013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simple subgroup approximations to optimal treatment regimes from randomized clinical trial data.
    Foster JC; Taylor JM; Kaciroti N; Nan B
    Biostatistics; 2015 Apr; 16(2):368-82. PubMed ID: 25398774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous evaluation of the harms and benefits of treatments in randomized clinical trials: demonstration of a new approach.
    Frank E; Kupfer DJ; Rucci P; Lotz-Wallace M; Levenson J; Fournier J; Kraemer HC
    Psychol Med; 2012 Apr; 42(4):865-73. PubMed ID: 21861951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using pilot data to size a two-arm randomized trial to find a nearly optimal personalized treatment strategy.
    Laber EB; Zhao YQ; Regh T; Davidian M; Tsiatis A; Stanford JB; Zeng D; Song R; Kosorok MR
    Stat Med; 2016 Apr; 35(8):1245-56. PubMed ID: 26506890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.